Burnett et al. 1 noted that certain chronic schizophrenic. Does Tardive Dysmentia Really Exist? CLINICAL AND RESEARCH REPORTS

Size: px
Start display at page:

Download "Burnett et al. 1 noted that certain chronic schizophrenic. Does Tardive Dysmentia Really Exist? CLINICAL AND RESEARCH REPORTS"

Transcription

1 CLINICAL AND RESEARCH REPORTS Does Tardive Dysmentia Really Exist? Sagar Lavania, M.B.B.S, M.D., D.P.M. Samir Kumar Praharaj, M.B.B.S, M.D., D.P.M. Hariender Singh Bains, M.R.C.P. (Psych.) Sudhir Kumar, M.B.B.S, M.D. Dinesh Malkan Singh Rathore, M.B.B.S, M.D. Sandhya Mohanty, Ph.D. Madhu Nayak, M.B.B.S, M.D. Tardive dysmentia has been described as the behavioral equivalent of tardive dyskinesia in patients with schizophrenia. Its association with tardive dyskinesia and psychopathology has been controversial. The authors assessed 123 inpatients with chronic schizophrenia for presence of tardive dysmentia symptoms/signs. Psychopathology and tardive dyskinesia were also assessed. Of the group, 24 patients (19.5%) had at least one tardive dysmentia symptom/sign, whereas only 1 patient (0.8%) fulfilled the syndromal criteria for tardive dysmentia. Those with tardive dysmentia had higher psychopathology scores, higher Abnormal Involuntary Movement Scale total scores, higher number of women and family psychiatric illness, and higher rates of persistent tardive dyskinesia. Tardive dysmentia symptoms/signs are frequently seen in chronic schizophrenia, but the complete syndrome may be rare. (The Journal of Neuropsychiatry and Clinical Neurosciences 2013; 25:58 62) Burnett et al. 1 noted that certain chronic schizophrenic patients with severe tardive dyskinesia presented with behavior resembling that of hypomania as well as schizophrenia. These patients tended to be loquacious and to speak in a loud voice. Wilson et al. 2 studied this phenomenon in 29 schizophrenia patients and coined the term tardive dysmentia as the behavioral equivalent of tardive dyskinesia. It is described as a behavioral syndrome in schizophrenia characterized by a triad of symptoms/signs: alteration in 1) affect; 2) activation level; and 3) interpersonal interaction. Since the time term tardive dysmentia was coined by Wilson et al., 2 research papers have been published questioning the validity of the term. Mukherjee 3 reassessed the concept of tardive dysmentia and discouraged the use of dysmentia on phenomenological grounds. Also, the association with tardive dyskinesia was challenged, based on the observation that such syndrome was absent in bipolar patients with tardive dyskinesia after long-term exposure to antipsychotics. 3 Mukherjee and Bilder 4 reported that there is no evidence that the syndrome is tardive or iatrogenic in nature and that it may be a manifestation of schizophrenia. Perenyi et al. 5 found this phenomenon to be very rare and suggested retaining the term tardive dysmentia until a better characterization is found. Tardive dysmentia has been associated with various risk factors. Studies have related tardive dysmentia with the severity of tardive dyskinesia, 2 duration of antipsychotic exposure, 2 and phenomenology and pathophysiology of schizophrenia. 3 There is lack of consensus on whether the tardive dysmentia is primarily related to disease process or is iatrogenic in origin. Furthermore, although various risk factors for tardive dysmentia have been suggested in patients with schizophrenia, only a small proportion develops this condition. Understanding these risk factors would have far-reaching implications on prognosis, treatment, and understanding of the disorder. Only a handful of studies on tardive dysmentia have been systematically done todate. Therefore, we aimed to assess the prevalence of tardive dysmentia and its relationship with tardive dyskinesia and psychopathology in patients with chronic schizophrenia. Received February 6, 2012; revised June 17, 2012; accepted July 10, From the Dept. of Psychiatry, Sarojini Naidu Medical College, Agra, India; Dept. of Psychiatry, Kasturba Medical College, Manipal, Karnataka, India; Nottinghamshire Healthcare NHS Trust, Kingsfield Resource Centre, Surrey, UK; Institute of Mental Health & Hospital, Agra, India; Department of Paediatrics, Netaji Subhash Chand Bose Medical College, Jabalpur, Madhya Pradesh, India. Send correspondence to Dr. Samir Kumar Praharaj, M.B.B.S, M.D., D.P.M., Dept. of Psychiatry, Kasturba Medical College, Manipal, Karnataka, India; samirpsyche@yahoo.co.in Copyright 2013 American Psychiatric Association 58 J Neuropsychiatry Clin Neurosci 25:1, Winter 2013

2 LAVANIA et al. METHODS Sample This was cross-sectional, hospital-based study conducted at Institute of Mental Health (IMH) and Hospital, Agra, India. The study was approved by the institutional ethics committee. The sample consisted of male and female inpatients fulfilling criteria for schizophrenia according to ICD-10 Diagnostic Criteria for Research, 6 having chronic illness (duration of illness of 2 years or more) and giving written informed consent. Those with comorbid mental retardation or major medical or neurological illness were excluded from the study. Assessment Tools A datasheet specially designed for the study was used to collect sociodemographic and clinical details of the patients. To diagnose tardive dysmentia, Wilson et al. 2 criteria were used. Emotional behavior was rated on five symptoms/signs: 1) depressed-to-euphoric mood; 2) stable-to-labile or unstable mood; 3) quiet-to-loud speech; 4) paucity-to-excess of words; and 5) retreat-to-approach to the examiner, using 100-mm line tests as described by Wilson et al. 2 To assess schizophrenic psychopathology, the 30-item Positive and Negative Syndrome Scale (PANSS) 7 was used. The PANSS is based on the premise that schizophrenia has two distinct syndromes, a positive syndrome including delusions, hallucinations, and so forth, and a negative syndrome, involving features such as affective flattening and alogia. To characterize tardive dyskinesia, the Abnormal Involuntary Movement Scale (AIMS), 8 a 12-item instrument utilized to provide a numeric measure to the observed abnormal movements in different parts of the body, was used. The information is scored on a 5-point scale (0: none; 4: severe). Test retest reliability ranges from 0.40 to 0.82 for individual items and is 0.71 for overall severity. Research diagnoses for tardive dyskinesia 9 were used to classify tardive dyskinesia subtype. These has been suggested to help study the epidemiology, etiology, and treatment of tardive dyskinesia patients. Tardive dyskinesia is divided into six groups: probable tardive dyskinesia, masked probable tardive dyskinesia, transient tardive dyskinesia, withdrawal tardive dyskinesia, persistent tardive dyskinesia, and masked persistent tardive dyskinesia. 9 Procedures Case record files of inpatients of the IMH, Agra were screened to identify patients with schizophrenia. For those fulfilling inclusion criteria, a detailed mental status examination was done to confirm the diagnosis, after obtaining written informed consent. Sociodemographic and clinical details were recorded in the semistructured datasheet. Detailed physical and neurological examination was done to rule out medical comorbidity. Tardive dysmentia was assessed using Wilson et al. 2 criteria to characterize two groups: schizophrenia patients with and without tardive dysmentia. All the patients were rated on PANSS, AIMS, and Global Assessment of Functioning (GAF). Tardive dyskinesia was classified using Schooler and Kane criteria. 9 The ratings were done by two authors, SL and DMSR. To assess interrater reliability, the first 25 patients were assessed by both raters. Statistical Analysis Data obtained were analyzed with the Statistical Package for Social Sciences (SPSS) Version 10.0 for Windows. Normality of data were examined with the Shapiro-Wilk test statistic. To examine interrater reliability, Spearman s rank correlation coefficient was calculated for 25 patients. To compare patients with or without tardive dysmentia, the Mann-Whitney U test and Pearson s chi-square test were used for continuous and categorical variables, respectively. A p value of,0.05 (two-tailed) was considered significant. RESULTS Sample characteristics as described by the Mann- Whitney U test and Pearson s chi-square (with effect size) test are summarized in Table 1 and Table 2. The mean age of patients was (standard deviation [SD]: 9.42; range: 19 62) years, and mean illness duration was 9.32 (SD: 6.36; range: 2 40) years. Mean level of formal education was 8.23 (SD: 4.69) years. Ninety-one patients (74%) were men; 53 (43.1%) were single; 34 (27.6%) were unemployed before admission to the hospital; 84 (68.3%) were of lower socioeconomic status; and 75 (61%) were from a rural background. Interrater reliability, as seen using Spearman s rank coefficient of correlation, was the following: PANSS Positive score, 0.97 (p,0.001); PANSS Negative score, 0.96 (p,0.001); PANSS General psychopathology score, 0.89 (p,0.001); PANSS Total score, 0.93 (p,0.001); AIMS total score, 0.70 (p,0.001); euphoria, 0.97 (p,0.001); unstable mood, 0.95 (p,0.001); loud speech, 0.90 (p,0.001); J Neuropsychiatry Clin Neurosci 25:1, Winter

3 DOES TARDIVE DYSMENTIA REALLY EXIST? TABLE 1. Comparison of Socio-Demographic and Clinical Characteristics Without TDm (N=99) With TDm (N=24) Mann- Whitney U (Z) p Age, years (9.10) (10.76) 1, Median (range) 34 (42) 34 (38) (20.39) Education years 8.13 (4.56) 8.63 (5.31) 1, Median (range) 8 (17) 9 (17) (20.51) Illness duration, years 9.09 (6.45) (5.98) 1, Median (range) 7 (38) 9.50 (23.5) (21.19) PANSS Positive 9.93 (4.30) (5.47) 815.5* Median (range) 8 (20) 12 (25) (22.47) PANSS Negative (7.77) (6.04) 1, Median (range) 8 (28) 8.5 (20) (20.17) PANSS General psychopathology (7.67) (5.07) Median (range) 18 (43) 20.5 (16) (21.72) PANSS Total (17.80) (14.15) Median (range) 35 (97) 43 (56) (21.66) AIMS Total 0.42 (1.86) 0.96 (2.49) 1, Median (range) 0 (10) 0 (9) (21.89) Antipsychotics dose (chlorpromazine equivalent) (214.95) (208.86) Median (range) 300 (1400) 300 (850) (21.25) Values are mean (standard deviation), unless otherwise indicated. TDm: Tardive dysmentia. *p,0.05 (two-tailed). excessive words, 0.87 (p,0.001); and approach to examiner, 0.89 (p,0.001). Mean PANSS Positive scores were significantly higher in patients with tardive dysmentia symptoms/signs than those without (p=0.014), and there was a trend toward higher scores in PANSS Total score and General psychopathology scores. A trend toward higher mean AIMS total scores was also seen in patients with tardive dysmentia symptoms/signs than those without (p=0.059). There was no difference in illness duration and antipsychotics dose between the two groups. Women were significantly more frequent among those with tardive dysmentia symptoms/signs than those without (p=0.014), although the effect size was small. Also, family psychiatric TABLE 2. Comparison of Socio-Demographic and Clinical Characteristics, N (%) Without TDm (N=99) With TDm a (N=24) x 2 p Effect size (f) Sex Male 78 (78.8) 13 (54.2) 6.08* Female 21 (21.2) 11 (45.8) Marital status Single 43 (43.4) 10 (41.7) 0.03 NS Married 56 (56.6) 14 (58.3) Occupation Unemployed 24 (24.2) 10 (41.7) Employed 75 (75.8) 14 (58.3) SES Lower 68 (68.7) 16 (66.7) 0.04 NS Middle 31 (31.3) 8 (33.3) Family type Nuclear 25 (25.3) 6 (25) 0.01 NS Joint 74 (74.7) 18 (75) Domicile Rural 59 (59.6) 16 (66.7) 0.41 NS Urban 40 (40.4) 8 (33.3) Schizophrenia subtype Paranoid 58 (58.6) 15 (62.5) 0.12 NS Nonparanoid 41 (41.4) 9 (37.5) Comorbid substance dependence Absent 53 (53.5) 18 (75) Present 46 (46.5) 6 (25) Family psychiatric illness Absent 83 (83.8) 12 (50) 12.58**, Present 16 (16.2) 12 (50) TD (Schooler & Kane) 9 Absent 96 (97) 20 (83.3) 6.69* Persistent 3 (3) 4 (16.7) TDm: Tardive dysmentia; TD: Tardive dyskinesia; Having at least one symptom of TDm; SES: socio-economic status. a Having at least one symptom of TDm. *p,0.05. **p,0.001 (two-tailed) J Neuropsychiatry Clin Neurosci 25:1, Winter 2013

4 LAVANIA et al. illness was higher in the tardive dysmentia symptoms/ signs group (p,0.001), with moderate effect size. Furthermore, trend toward a higher (16.7%) rate of persistent tardive dyskinesia was noted in those with tardive dysmentia symptoms/signs than those without (p=0.1), with small effect size. The frequency of tardive dysmentia symptoms/signs were the following: 9 (7.3%) had euphoria; 7 (5.7%) had unstable mood; 17 (13.8%) had loud speech; 12 (9.8%) had excessive words; and 3 (2.4%) had approach to examiner. Ninety-nine (80.5%) had no symptoms/signs; 24 (19.5%) had at least one symptom/sign; 16 (13%) had at least two symptoms/signs; 6 (4.9%) had at least three symptoms/signs; 2 (1.6%) had four symptoms/signs; and none had all five symptoms/signs. Only one patient (0.8%) fulfilled the Wilson et al. 2 criteria for tardive dysmentia, that is, having all three symptoms/signs: unstable mood, loud speech, and approach to the examiner. Spearman s rank correlation between individual tardive dysmentia symptoms/signs with psychopathology showed a significant positive correlation of PANSS Positive symptoms with unstable mood (r s =0.57; p=0.004) and excessive words (r s =0.52; p=0.009; Figure 1[A] and Figure 1[B]), and a trend toward positive correlation with loud speech (r s =0.39; p=0.06) and approach to examiner (r s =0.37; p=0.074). There was no correlation with PANSS Negative, General psychopathology, or Total score, and AIMS total score with any of tardive dysmentia symptoms/signs. There was no correlation of tardive dysmentia symptoms/signs with duration of illness or antipsychotics dose. FIGURE 1. Unstable Mood Excessive Words A B Scatterplot Showing Correlation of PANSS Positive Score With Tardive Dysmentia Symptoms (With Regression Line) (N=24) PANSS Positive Score DISCUSSION Results of our study show that tardive dysmentia symptoms/signs are fairly common in chronic schizophrenia patients, whereas, tardive dysmentia, as defined by Wilson et al., 2 is uncommon. Our study supports the hypothesis that these symptoms/signs are related to positive symptoms of schizophrenia, 3 with moderate-tohigh effect sizes. Although these symptoms/signs were not related to antipsychotic dose, a trend toward higher symptoms/signs was noted in those with tardive dyskinesia, with small effect size. Moreover, these symptoms/signs correlated with higher level of persistent tardive dyskinesia by Schooler and Kane 9 criteria. These findings are in contradiction to the reports of association of tardive dyskinesia with negative symptoms PANSS Positive Score [A] With Unstable Mood; [B] With Excessive Words of schizophrenia, 10,11 although, in recent studies, 12 they show correlation with positive symptoms, as well. It is also interesting to note that the symptoms/signs of tardive dysmentia have a superficial resemblance to hypomanic or manic symptoms. There have been reports of a possible association between tardive dyskinesia and affective disorders. 13 It also raises the possibility of the usefulness of mood stabilizers in the treatment of such symptoms/signs. Furthermore, tardive dysmentia symptoms/signs were more common in women and J Neuropsychiatry Clin Neurosci 25:1, Winter

5 DOES TARDIVE DYSMENTIA REALLY EXIST? those with a family history of psychiatric illness, with small-to-moderate effect sizes, respectively. Similar female predominance has also been reported in tardive dyskinesia studies. 14 The mechanisms of these symptoms/signs are poorly understood. Dopamine receptor supersensitivity after prolonged antipsychotics exposure, as proposed for tardive dyskinesia, may be an underlying mechanism for tardive dysmentia. 2,15,16 Jones 17 argued against such hypothesis and introduced the concept of cholinergic system dysfunction in tardive dysmentia. Correlation with positive symptoms suggests a common psychopathological mechanism for tardive dysmentia symptoms/ signs. The common pathway for expression of both these conditions could probably be through involvement of cortico subcortical circuits. 18,19 Interestingly, dopamine receptor supersensitivity has been suggested as the final common state resulting from multiple pathways that converge to elevate the dopamine levels in various brain areas. 20 Alternatively, the etiology of tardive dysmentia may be multifactorial, with one mechanism predominating in a subset of such patients. Neurobiological studies in these patients would reveal further insights into this phenomenon and the possible treatment strategies. In summary, tardive dysmentia symptoms/signs are frequently seen in patients with schizophrenia, but the complete syndrome may be rare. Besides correlation with psychopathology and tardive dyskinesia, which may provide clues to the neurobiological mechanisms, there are clinical implications also. The symptoms/signs of tardive dysmentia may lead to misdiagnosis of patients with schizophrenia by an unwary examiner as bipolar or schizoaffective disorder. Although our study had a large sample size, it may not be sufficient to characterize the true prevalence of this syndrome, and further studies are required. Another limitation is that all patients were chronically institutionalized, and, hence, these findings cannot be generalized to other population. Future studies may be designed to include schizophrenia patients from the community to overcome the effects of institutionalization and characterize the true prevalence of these symptoms/signs. This work was carried out at the Institute of Mental Health & Hospital, Agra, India. References 1. Burnett GB, Prange AJ Jr, Wilson IC, et al: Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia: an investigation of mechanism. Neuropsychobiology 1980; 6: Wilson IC, Garbutt JC, Lanier CF, et al: Is there a tardive dysmentia? Schizophr Bull 1983; 9: Mukherjee S: Tardive dysmentia: a reappraisal. Schizophr Bull 1984; 10: Mukherjee S, Bilder RM: Tardive dysmentia: further comments. Schizophr Bull 1985; 11: Perényi A, Goswami U, Zádor G, et al: Tardive dysmentia in Hungary. Biol Psychiatry 1988; 23: World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders Diagnostic Criteria for Research. Geneva, WHO, Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: Guy D: Abnormal Involuntary Movement Scale, in ECDEU Assessment Manual for Psychopharmacology. Rev. Ed. (DHEW publication (ADM) ). Rockville, MD: National Institute of Mental Health; Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: Waddington JL, Youssef HA: Late-onset involuntary movements in chronic schizophrenia: relationship of "tardive" dyskinesia to intellectual impairment and negative symptoms. Br J Psychiatry 1986; 149: Waddington JL, Youssef HA, Dolphin C, et al: Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia: their association in relation to topography of involuntary movements and criterion of their abnormality. Arch Gen Psychiatry 1987; 44: Miller DD, McEvoy JP, Davis SM, et al: Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE Schizophrenia Trial. Schizophr Res 2005; 80: Rosenbaum AH, Niven RG, Hanson NP, et al: Tardive dyskinesia: relationship with a primary affective disorder. Dis Nerv Syst 1977; 38: Yassa R, Jeste DV: Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992; 18: Andrew HG: Clinical relationship of extrapyramidal symptoms and tardive dyskinesia. Can J Psychiatry 1994; 39(Suppl 2):S76 S Kostrzewa RM, Kostrzewa JP, Brown RW, et al: Dopamine receptor supersensitivity: development, mechanisms, presentation, and clinical applicability. Neurotox Res 2008; 14: Jones BD: Tardive dysmentia : further comments. Schizophr Bull 1985; 11: Deutch AY: Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson s disease. J Neural Transm 1993; 91: Bonelli RM, Cummings JL: Frontal-subcortical circuitry and behavior. Dialogues Clin Neurosci 2007; 9: Seeman P, Schwarz J, Chen JF, et al: Psychosis pathways converge via D2 high dopamine receptors. Synapse 2006; 60: J Neuropsychiatry Clin Neurosci 25:1, Winter 2013

Chapter 1.4. Intermittent neuroleptic treatment is a risk factor for tardive dyskinesia

Chapter 1.4. Intermittent neuroleptic treatment is a risk factor for tardive dyskinesia Intermittent neuroleptic treatment is a risk factor for tardive dyskinesia The Curaçao Extrapyramidal Syndromes Study: III. Peter N. van Harten (1,3), Hans W. Hoek (2), Glenn E. Matroos (3), Maarten Koeter

More information

Bizarre delusions and DSM-IV schizophrenia

Bizarre delusions and DSM-IV schizophrenia Psychiatry and Clinical Neurosciences (2002), 56, 391 395 Regular Article Bizarre delusions and DSM-IV schizophrenia MAKOTO NAKAYA, md, phd, 1 KATSUNORI KUSUMOTO, md, phd, 2 TAKAYUKI OKADA, md, phd 3 AND

More information

BADDS Appendix A: The Bipolar Affective Disorder Dimensional Scale, version 3.0 (BADDS 3.0)

BADDS Appendix A: The Bipolar Affective Disorder Dimensional Scale, version 3.0 (BADDS 3.0) BADDS Appendix A: The Bipolar Affective Disorder Dimensional Scale, version 3.0 (BADDS 3.0) General information The Bipolar Affective Disorder Dimension Scale (BADDS) has been developed in order to address

More information

THE STABILITY OF SYMPTOMS AND SYNDROMES IN CHRONIC SCHIZOPHRENIC PATIENTS MILIND BORDE 1, ELIZABETH J.B. DAVIS 1 AND L.N. SHARMA 2

THE STABILITY OF SYMPTOMS AND SYNDROMES IN CHRONIC SCHIZOPHRENIC PATIENTS MILIND BORDE 1, ELIZABETH J.B. DAVIS 1 AND L.N. SHARMA 2 Indian J. Psychiat. 1992, 34(2), 133-139 THE STABILITY OF SYMPTOMS AND SYNDROMES IN CHRONIC SCHIZOPHRENIC PATIENTS MILIND BORDE 1, ELIZABETH J.B. DAVIS 1 AND L.N. SHARMA 2 36 chronic schizophrenic patients

More information

Clinical Guidelines for the Pharmacologic Treatment of Schizophrenia

Clinical Guidelines for the Pharmacologic Treatment of Schizophrenia Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare

More information

Initial Prodrome Description in Recent Onset Schizophrenia

Initial Prodrome Description in Recent Onset Schizophrenia Amr El-Shribiny et al. Initial Prodrome Description in Recent Onset Schizophrenia Amr M M El-Shribiny, Salwa M. Rabie, Hanaa S. Soliman, Refaat Mahfouz Department of Neurology and Psychiatry, El-Minia

More information

Schizoaffective Disorder

Schizoaffective Disorder Roseanna Parkhurst-Gatewood MSN FNP-BC, PMHNP-BC DSM-5 diagnostic criteria for schizoaffective disorder 3 A. An uninterrupted period of illness during which there is a major mood episode (major depressive

More information

THERAPEUTIC AND EVOLUTIVE ASPECTS IN SCHIZOPHRENIA

THERAPEUTIC AND EVOLUTIVE ASPECTS IN SCHIZOPHRENIA UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA THERAPEUTIC AND EVOLUTIVE ASPECTS IN SCHIZOPHRENIA ABSTRACT Ph.D. Coordinator Professor Dragoș MARINESCU PhD Student: Mihai MUTICĂ Craiova 2016 TABLE OF CONTENTS

More information

Presented at the American Psychiatric Association Annual Meeting May 20 24, 2017 San Diego, CA.

Presented at the American Psychiatric Association Annual Meeting May 20 24, 2017 San Diego, CA. Original Presentations Key Words: amines, antipsychotic agents, double-blind method, mood disorders, psychopharmacology, psychotic disorders, schizophrenia, tardive dyskinesia, valbenazine Efficacy of

More information

Social Factors and Psychopathology in Epilepsy

Social Factors and Psychopathology in Epilepsy ORIGINAL ARTICLE Social Factors and Psychopathology in Epilepsy N. Cyriac, P.N. Sureshkumar, A.M. Kunhikoyamu, A.S. Girija* Departments of Psychiatry and Neurology* Medical College Calicut, Kerala, India.

More information

Characteristics of trees drawn by patients with paranoid schizophrenia

Characteristics of trees drawn by patients with paranoid schizophrenia PCN Psychiatric and Clinical Neurosciences 1323-13162003 Blackwell Science Pty Ltd 574August 2003 1130 Schizophrenia and tree-drawing morphology H. Inadomi et al. 10.1046/j.1323-1316.2003.01130.x Original

More information

EVALUATION OF WORRY IN PATIENTS WITH SCHIZOPHRENIA AND PERSECUTORY DELUSION COMPARED WITH GENERAL POPULATION

EVALUATION OF WORRY IN PATIENTS WITH SCHIZOPHRENIA AND PERSECUTORY DELUSION COMPARED WITH GENERAL POPULATION Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 7 (56) No. 1-2014 EVALUATION OF WORRY IN PATIENTS WITH SCHIZOPHRENIA AND PERSECUTORY DELUSION COMPARED WITH GENERAL POPULATION

More information

PROVIDED IN RESPONSE TO YOUR UNSOLICITED REQUEST FOR INFORMATION

PROVIDED IN RESPONSE TO YOUR UNSOLICITED REQUEST FOR INFORMATION KINECT 2 NCT01733121 Baseline Week 2 Week 4 Week 6 Valbenazine 25-75 mg Valbenazine 40 mg KINECT 3 NCT02274558 Valbenazine 80 mg a KINECT 2 and KINECT 3 were 6-week, double-blind placebo-controlled trials

More information

Relationship between Positive and Negative Symptoms of Schizophrenia and Psychotic Depression with Risk of Suicide

Relationship between Positive and Negative Symptoms of Schizophrenia and Psychotic Depression with Risk of Suicide Original Article Relationship between Positive and Negative Symptoms of Schizophrenia and Psychotic Depression with Risk of Suicide Ebrahim Abdollahian, MD *, Morterza Modares Gharavi, PhD * Atefeh Soltanifar,

More information

Burden among Caregivers of Person with Schizophrenia and. Schizoaffective Disorder: A Comparative Study

Burden among Caregivers of Person with Schizophrenia and. Schizoaffective Disorder: A Comparative Study The International Journal of Indian Psychology ISSN 2348-5396 (e) ISSN: 2349-3429 (p) Volume 2, Issue 4, DIP: B00388V2I42015 http://www.ijip.in July September, 2015 Burden among Caregivers of Person with

More information

A 10-YEAR FOLLOW-UP STUDY OF TARDIVE DYSKINESIA-WITH SPECIAL REFERENCE TO THE INFLUENCE OF NEUROLEPTIC ADMINISTRATION ON THE LONG-TERM PROGNOSIS

A 10-YEAR FOLLOW-UP STUDY OF TARDIVE DYSKINESIA-WITH SPECIAL REFERENCE TO THE INFLUENCE OF NEUROLEPTIC ADMINISTRATION ON THE LONG-TERM PROGNOSIS Keio Journal of Medicine 34: 211-219, 1985 ORIGINAL ARTICLES A 10-YEAR FOLLOW-UP STUDY OF TARDIVE DYSKINESIA-WITH SPECIAL REFERENCE TO THE INFLUENCE OF NEUROLEPTIC ADMINISTRATION ON THE LONG-TERM PROGNOSIS

More information

Effectiveness of Cognitive Behaviour Therapy on Patients Suffering From Depression

Effectiveness of Cognitive Behaviour Therapy on Patients Suffering From Depression The International Journal of Indian Psychology ISSN 2348-5396 (e) ISSN: 2349-3429 (p) Volume 3, Issue 4, No. 64, DIP: 18.01.119/20160304 ISBN: 978-1-365-32519-9 http://www.ijip.in July-September, 2016

More information

DESIGN TYPE AND LEVEL OF EVIDENCE: Randomized controlled trial, Level I

DESIGN TYPE AND LEVEL OF EVIDENCE: Randomized controlled trial, Level I CRITICALLY APPRAISED PAPER (CAP) Hasan, A. A., Callaghan, P., & Lymn, J. S. (2015). Evaluation of the impact of a psychoeducational intervention for people diagnosed with schizophrenia and their primary

More information

Tactile, Olfactory, and Gustatory Hallucinations in Psychotic Disorders: A Descriptive Study

Tactile, Olfactory, and Gustatory Hallucinations in Psychotic Disorders: A Descriptive Study Original Article 383 Tactile, Olfactory, and Gustatory Hallucinations in Psychotic Disorders: A Descriptive Study Kathryn E Lewandowski, 1,2 PhD, Joseph DePaola, 1,2 BA, Gamze B Camsari, 1 MD, Bruce M

More information

A Case of Hyper Sexuality Probably Associated with Clozapine

A Case of Hyper Sexuality Probably Associated with Clozapine Complicated Case Histories Key Words: atypical antipsychotic, adverse drug reaction, hypersexuality A Case of Hyper Sexuality Probably Associated with Clozapine By Sereen Rose Thomson, Navin Patil, Balaji

More information

Delirium in Hospitalised Patients A Study Of Clinical and Psychosocial Profiles

Delirium in Hospitalised Patients A Study Of Clinical and Psychosocial Profiles IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 10 Ver. IV (Oct. 2017), PP 45-49 www.iosrjournals.org Delirium in Hospitalised Patients A Study

More information

Treatment Efficacy and Quality of Life after Modified ECT in Manic Patients

Treatment Efficacy and Quality of Life after Modified ECT in Manic Patients International Journal of Scientific and Research Publications, Volume 8, Issue 2, February 2018 306 Treatment Efficacy and Quality of Life after Modified ECT in Manic Patients Dr. Madhu Shrama, Dept. of

More information

Challenges to Recovery Following Early Psychosis: Implications of Recovery Rate and Timing

Challenges to Recovery Following Early Psychosis: Implications of Recovery Rate and Timing Challenges to Recovery Following Early Psychosis: Implications of Recovery Rate and Timing Mental Health Exchange Group December 3, 2014 W Joy Maddigan, PhD RN Background One component [the quantitative

More information

Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies

Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies Henry A. Nasrallah, MD Sydney W. Souers Professor and Chair, Department of Psychiatry, Saint Louis University,

More information

Not an actual patient

Not an actual patient www.takeontd.com TD CAN BE A BURDEN ON PATIENTS AND AFFECT THEIR LIVES 1 TD can be disruptive, whether they have mild, moderate, or severe TD. 2 Patients with TD may deal with many issues Abnormal and

More information

Chapter 12 1/29/2018. Schizophrenia and Schizophrenia Spectrum Disorders. Epidemiology. Comorbidity. Lifetime prevalence of schizophrenia is 1%

Chapter 12 1/29/2018. Schizophrenia and Schizophrenia Spectrum Disorders. Epidemiology. Comorbidity. Lifetime prevalence of schizophrenia is 1% Chapter 12 Schizophrenia and Schizophrenia Spectrum Disorders Epidemiology Lifetime prevalence of schizophrenia is 1% No difference related to 2 Comorbidity Substance abuse disorders Anxiety, depression,

More information

Julio Bobes, MD, PhD; Celso Arango, MD, PhD; Margarida Garcia-Garcia, MSc; and Javier Rejas, MD, PhD; for the CLAMORS Study Collaborative Group

Julio Bobes, MD, PhD; Celso Arango, MD, PhD; Margarida Garcia-Garcia, MSc; and Javier Rejas, MD, PhD; for the CLAMORS Study Collaborative Group Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice: Findings From the CLAMORS Study Julio Bobes, MD, PhD; Celso

More information

Research Article JIACAM Vol. 1, No. 3, Article 6

Research Article JIACAM Vol. 1, No. 3, Article 6 Research Article JIACAM Vol. 1, No. 3, Article 6 Clinical Profile of Childhood Onset Schizophrenia in India* I. Sharma 1, D. Giri 2, Anna Dutta 3, P. Mazumder 4 & Mrs Anuradha 5 Department of Psychiatry

More information

Class Update: Oral Antipsychotics

Class Update: Oral Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

SCHRES1520. Schizophrenia Research 000 (2001) 000±000. Affective reactivity of language and right-ear advantage in schizophrenia

SCHRES1520. Schizophrenia Research 000 (2001) 000±000. Affective reactivity of language and right-ear advantage in schizophrenia SCHRES1520 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 Abstract Affective reactivity of language and right-ear

More information

Schizophrenia FAHAD ALOSAIMI

Schizophrenia FAHAD ALOSAIMI Schizophrenia FAHAD ALOSAIMI MBBS, SSC - PSYCH C ONSULTATION LIAISON PSYCHIATRIST K ING SAUD UNIVERSITY Schizophrenia - It is not a single disease but a group of disorders with heterogeneous etiologies.

More information

Clozapine Treatment and Predictors of Response in Patients with Schizophrenia

Clozapine Treatment and Predictors of Response in Patients with Schizophrenia KISEP Original Article Clinical Psychopharmacology and Neuroscience 2003; 1: 22-6 Clozapine Treatment and Predictors of Response in Patients with Schizophrenia Chul Eung Kim, Sang Eun Shin, Min Hee Kang

More information

Introduction. original article. Camilla Callegari Ivano Caselli Marta Ielmini Simone Vender E-bPC

Introduction. original article. Camilla Callegari Ivano Caselli Marta Ielmini Simone Vender E-bPC original article Camilla Callegari Ivano Caselli Marta Ielmini Simone Vender Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Insubria, Varese, Italy Influence of

More information

A cross sectional study on prevalence and pattern of personality disorders in psychiatric inpatients of a tertiary care hospital

A cross sectional study on prevalence and pattern of personality disorders in psychiatric inpatients of a tertiary care hospital Original Research Article A cross sectional study on prevalence and pattern of personality disorders in psychiatric inpatients of a tertiary care hospital Maanasa T J 1*, Sivabackiya C 1, Srinivasan B

More information

Routine clinical measures in a newly commissioned Psychiatric Intensive Care Unit (PICU): Predictors of favourable outcomes.

Routine clinical measures in a newly commissioned Psychiatric Intensive Care Unit (PICU): Predictors of favourable outcomes. Routine clinical measures in a newly commissioned Psychiatric Intensive Care Unit (PICU): Predictors of favourable outcomes. Rebecca Carleton, 1 Matthew Cordiner, 1 Patrick Hughes, 1 Susan Cochrane, 1

More information

University of Groningen. Neurological soft signs in schizophrenia and mood disorders Boks, Marco Paul Maria

University of Groningen. Neurological soft signs in schizophrenia and mood disorders Boks, Marco Paul Maria University of Groningen Neurological soft signs in schizophrenia and mood disorders Boks, Marco Paul Maria IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish

More information

CHAPTER 3. Schizophrenia and Antipsychotic Treatment

CHAPTER 3. Schizophrenia and Antipsychotic Treatment CHAPTER 3 Schizophrenia and Antipsychotic Treatment What is it? It is a severe, chronic, disabling brain disease Considered to have biological origins but exact unknown 1% of population affected Schizophrenia

More information

Schizophrenia. Class Objectives. Can someone be psychotic without having schizophrenia? 12/7/2011. Other psychotic disorders and causes

Schizophrenia. Class Objectives. Can someone be psychotic without having schizophrenia? 12/7/2011. Other psychotic disorders and causes Schizophrenia Other psychotic disorders and causes Class Objectives What are Delusional Disorders? What causes Schizophrenia? How can Schizophrenia be treated? Can someone be psychotic without having schizophrenia?

More information

The psychological disorders

The psychological disorders The psychological disorders Defining abnormal Statistical infrequency Normal distribution; the normal curve Violation of norms Culture bound syndromes Personal distress Some disorders do not involve distress

More information

MENTAL HEALTH DISEASE CLASSIFICATIONS

MENTAL HEALTH DISEASE CLASSIFICATIONS MENTAL HEALTH DISEASE CLASSIFICATIONS DIAGNOSIS OF MENTAL DISORDERS DSM-IV-TR Published by APA ( 2000 ) Multiaxial system 5 categories called axes Facilitate holistic assessment for care Is a great resource

More information

Mood Disorders for Care Coordinators

Mood Disorders for Care Coordinators Mood Disorders for Care Coordinators David A Harrison, MD, PhD Assistant Professor, Dept of Psychiatry & Behavioral Sciences University of Washington School of Medicine Introduction 1 of 3 Mood disorders

More information

METHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC

METHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC PREDICTORS OF MEDICATION ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIC DISORDERS TREATED WITH TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN A LARGE STATE MEDICAID PROGRAM S.P. Lee 1 ; K. Lang 2 ; J. Jackel 2 ;

More information

The Diagnostic Stability of DSM-IV Diagnoses: An Examination of Major Depressive Disorder, Bipolar I Disorder, and Schizophrenia in Korean Patients

The Diagnostic Stability of DSM-IV Diagnoses: An Examination of Major Depressive Disorder, Bipolar I Disorder, and Schizophrenia in Korean Patients Original Article pissn 1738-1088 / eissn 2093-4327 Clinical Psychopharmacology and Neuroscience 2011;9(3):117-121 Copyrightc 2011, Korean College of Neuropsychopharmacology The Diagnostic Stability of

More information

Rating Mental Impairment with AMA Guides 6 th edition:

Rating Mental Impairment with AMA Guides 6 th edition: Rating Mental Impairment with AMA Guides 6 th edition: Practical Considerations and Strategies CSME/CAPDA C-CAT Course, March 24, 2018 William H. Gnam, PhD, MD, FRCPC (william.gnam@gmail.com) Consultant

More information

Raman Krishnan 1,*, Sharma PSVN 2. Manipal. *Corresponding Author:

Raman Krishnan 1,*, Sharma PSVN 2. Manipal. *Corresponding Author: Original Research Article A comparative study of clinical correlates of bipolar mixed state with bipolar manic and bipolar depressed state in a general hospital psychiatry setting Raman Krishnan 1,*, Sharma

More information

Tracey G. Skale, MD Chief Medical Officer Greater Cincinnati Behavioral Health

Tracey G. Skale, MD Chief Medical Officer Greater Cincinnati Behavioral Health Schizophrenia: What Do We Know? Where Do We Go From Here? Tracey G. Skale, MD Chief Medical Officer Greater Cincinnati Behavioral Health Objectives Participants will be able to: Understand the clinical

More information

THE HAMILTON Depression Rating Scale

THE HAMILTON Depression Rating Scale Reliability and Validity of the Turkish Version of the Hamilton Depression Rating Scale A. Akdemir, M.H. Türkçapar, S.D. Örsel, N. Demirergi, I. Dag, and M.H. Özbay The aim of the study was to examine

More information

Recent Advances in the Antipsychotic Treatment of People with schizophrenia. Robert W. Buchanan, M.D.

Recent Advances in the Antipsychotic Treatment of People with schizophrenia. Robert W. Buchanan, M.D. Recent Advances in the Antipsychotic Treatment of People with schizophrenia Robert W. Buchanan, M.D. Antipsychotic medications are the primary class of drugs used in the pharmacological treatment of schizophrenia.

More information

Alternative Thresholds for Negative and Positive Symptoms in the CATIE Trial: Implications for Negative Symptom Clinical Trials

Alternative Thresholds for Negative and Positive Symptoms in the CATIE Trial: Implications for Negative Symptom Clinical Trials Alternative Thresholds for Negative and Positive Symptoms in the CATIE Trial: Implications for Negative Symptom Clinical Trials Eduardo Dunayevich, Chao-Yin Chen, Stephen Marder and Jonathan Rabinowitz

More information

Illness insight as a predictor of depression in elderly patients with a psychotic disorder.

Illness insight as a predictor of depression in elderly patients with a psychotic disorder. Illness insight as a predictor of depression in elderly patients with a psychotic disorder. F. A. Konings Master Thesis Clinical Psychology Faculty of social behavioural sciences Leiden University 19-01-2016

More information

Sociodemographic and clinical factors associated with relapse in schizophrenia

Sociodemographic and clinical factors associated with relapse in schizophrenia Psychiatry and Clinical Neurosciences (2007), 61, 587 593 doi:10.1111/j.1440-1819.2007.01722.x Regular Article Sociodemographic and clinical factors associated with relapse in schizophrenia GOBIND CHABUNGBAM,

More information

ENTITLEMENT ELIGIBILITY GUIDELINE SCHIZOPHRENIA

ENTITLEMENT ELIGIBILITY GUIDELINE SCHIZOPHRENIA Entitlement Eligibility Guideline SCHIZOPHRENIA Page 1 of 8 ENTITLEMENT ELIGIBILITY GUIDELINE SCHIZOPHRENIA MPC 00607 ICD-9 295 ICD-10 F20 DEFINITION SCHIZOPHRENIA Characteristic symptoms of Schizophrenia

More information

D. Exclusion of schizoaffective disorder and mood disorder with psychotic features.

D. Exclusion of schizoaffective disorder and mood disorder with psychotic features. 65 CHAPTER 8: APPENDIX. ADDENDUM A DSM-IV diagnostic criteria for schizophrenia A. Characteristic symptoms: Two or more of the following, each present for a significant portion of time during a one-month

More information

PSYCH 335 Psychological Disorders

PSYCH 335 Psychological Disorders PSYCH 335 Psychological Disorders Chapter 10 Schizophrenia and Psychotic Disorders Outline/Overview Schizophrenia Statistics/Impact/History Criteria Prognostic indicators/ suicide Epidemiology/correlates

More information

Psychosis and Agitation in Dementia

Psychosis and Agitation in Dementia Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University

More information

By Jason H. King DECONSTRUCTING THE DSM-5 ASSESSMENT AND DIAGNOSIS OF SCHIZOPHRENIA SPECTRUM DISORDERS THE NEW LANDSCAPE

By Jason H. King DECONSTRUCTING THE DSM-5 ASSESSMENT AND DIAGNOSIS OF SCHIZOPHRENIA SPECTRUM DISORDERS THE NEW LANDSCAPE DECONSTRUCTING THE DSM-5 By Jason H. King ASSESSMENT AND DIAGNOSIS OF SCHIZOPHRENIA SPECTRUM DISORDERS Happy New Year as you engage in your counseling, research, supervision or educational endeavors. I

More information

Effect of family intervention on functioning among patients with chronic schizophrenia

Effect of family intervention on functioning among patients with chronic schizophrenia Original article Sreeja, I: Effect of family intervention on functioning Effect of family intervention on functioning among patients with chronic schizophrenia Sreeja I Email: sreeja009@rediffmail.com

More information

Schizophrenia and the Psychoses

Schizophrenia and the Psychoses Schizophrenia and the Psychoses Taking leave of one s senses Students of schizophrenia need to study and understand: Clinical presentation via case studies Terms and Definitions Biological features Prognosis

More information

Schizophrenia. Positive Symptoms. Course of Schizophrenia. Psychotic Disorder

Schizophrenia. Positive Symptoms. Course of Schizophrenia. Psychotic Disorder Schizophrenia Kimberley Clow kclow2@uwo.ca http://instruct.uwo.ca/psychology/155b/ Outline What is Schizophrenia? Positive Symptoms Negative Symptoms Subtypes Phases Development Causes Treatment What Is

More information

ORIGINAL RESEARCH Key Words: psychometric evaluation, obsessive-compulsive disorder, co-morbidity, assessment

ORIGINAL RESEARCH Key Words: psychometric evaluation, obsessive-compulsive disorder, co-morbidity, assessment 025-030_PB_V39N1_de_Haan.qxd 9/21/06 5:35 PM Page 25 ORIGINAL RESEARCH Key Words: psychometric evaluation, obsessive-compulsive disorder, co-morbidity, assessment Reliability and Validity of the Yale-Brown

More information

Marital Adjustment Among Patients With Depression

Marital Adjustment Among Patients With Depression Marital Adjustment Among Patients With Depression [1] Anubha Srivastava Abstract: This study explored marital adjustment among patients with depression. Beck Depression Inventory-II (BDI-II) ( Beck, Steel

More information

Schizophrenia* London, Ontario, Canada Submitted: July 26, Accepted: November 18,1993. risperidone brought some

Schizophrenia* London, Ontario, Canada Submitted: July 26, Accepted: November 18,1993. risperidone brought some CASE REPORT Famotidine as an Adjunct Treatment of Resistant Schizophrenia* L.K. Oyewumi, D. Vollick, H. Merskey and C. Plumb Department of Psychiatry, University of Western Ontario, London Psychiatric

More information

Original Article INTRODUCTION. prefrontal cortex is mediated by a variety of mechanisms including 5HT1A agonism. [4,5]

Original Article INTRODUCTION. prefrontal cortex is mediated by a variety of mechanisms including 5HT1A agonism. [4,5] Original Article A triple-blinded, randomized, placebo-controlled trial to examine the efficacy of buspirone added to typical antipsychotic drugs in patients with chronic schizophrenia Fatemeh Sheikhmoonesi,

More information

Psychopathology, Disability & Family Burden of Patients with Schizophrenia and Bipolar Affective Disorders -A Comparison

Psychopathology, Disability & Family Burden of Patients with Schizophrenia and Bipolar Affective Disorders -A Comparison Original article DOI: http://dx.doi.org/10.18320/jimd/201603.0112 JOURNAL OF INTERNATIONAL MEDICINE AND DENTISTRY To search..to know...to share p-issn: 2454-8847 e-issn: 2350-045X Psychopathology, Disability

More information

Emotional Valence and Reference Disturbance in Schizophrenia

Emotional Valence and Reference Disturbance in Schizophrenia Journal of Abnormal Psychology Copyright 00 by the American Psychological Association, Inc. 00, Vol. 111, No. 1, 186 191 001-843X/0/$5.00 DOI: 10.1037//001-843X.111.1.186 Emotional Valence and Reference

More information

Open Journal of Psychiatry & Allied Sciences. Introduction ORIGINAL RESEARCH PAPER. Samrat Singh Bhandari 1, Dipesh Bhagabati 2

Open Journal of Psychiatry & Allied Sciences. Introduction ORIGINAL RESEARCH PAPER. Samrat Singh Bhandari 1, Dipesh Bhagabati 2 ISSN 2394-2053 (Print) ISSN 2394-2061 (Online) www.ojpas.com ORIGINAL RESEARCH PAPER Open Journal of Psychiatry & Allied Sciences Prevalence of spontaneous dyskinesia in first episode, drug naive schizophrenia,

More information

REVIEW. Innov Clin Neurosci. 2017;14(11 12):54 58

REVIEW. Innov Clin Neurosci. 2017;14(11 12):54 58 Understanding Antipsychotic Drug Treatment Effects: A Novel Method to Reduce Pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) Factors ABSTRACT The Positive and Negative Syndrome Scale

More information

Reviews and Overviews. Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies

Reviews and Overviews. Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies Reviews and Overviews Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies Christoph U. Correll, M.D. Stefan Leucht, M.D. John M. Kane,

More information

Mental Health Disorders Civil Commitment UNC School of Government

Mental Health Disorders Civil Commitment UNC School of Government Mental Health Disorders 2017 Civil Commitment UNC School of Government Edward Poa, MD, FAPA Chief of Inpatient Services, The Menninger Clinic Associate Professor, Baylor College of Medicine NC statutes

More information

CHAPTER 6: ANXIETY AND STRESSOR-RELATED PROBLEMS KEY TERMS

CHAPTER 6: ANXIETY AND STRESSOR-RELATED PROBLEMS KEY TERMS CHAPTER 6: ANXIETY AND STRESSOR-RELATED PROBLEMS KEY TERMS Affectionless Control A type of parenting characterized by high levels of overprotection combined with a lack of warmth and care. Amygdala The

More information

Schizophrenia: New Concepts for Therapeutic Discovery

Schizophrenia: New Concepts for Therapeutic Discovery Schizophrenia: New Concepts for Therapeutic Discovery William T. Carpenter, M.D. Professor of Psychiatry and Pharmacology University of Maryland School of Medicine Department of Psychiatry Maryland Psychiatric

More information

A Comparative Study of Socio Demographic and Clinical Profiles in Patient with Obsessive Compulsive Disorder and Depression

A Comparative Study of Socio Demographic and Clinical Profiles in Patient with Obsessive Compulsive Disorder and Depression American Journal of Psychiatry and Neuroscience 2018; 6(4): 99-103 http://www.sciencepublishinggroup.com/j/ajpn doi: 10.11648/j.ajpn.20180604.12 ISSN: 2330-4243 (Print); ISSN: 2330-426X (Online) A Comparative

More information

RANZCP 2010 AUCKLAND, NEW ZEALAND

RANZCP 2010 AUCKLAND, NEW ZEALAND RANZCP 2010 AUCKLAND, NEW ZEALAND Dr Veronica Stanganelli et al. RANZCP 2010 1 INTRODUCTION Bipolar disorder within young people has been debated for years. It is still controversial in DSM V (1), whether

More information

November 2014 MRC2.CORP.X.00004

November 2014 MRC2.CORP.X.00004 This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid consultant of Otsuka America Pharmaceutical, Inc. advice or professional diagnosis. Users seeking

More information

APPENDIX 11: CASE IDENTIFICATION STUDY CHARACTERISTICS AND RISK OF BIAS TABLES

APPENDIX 11: CASE IDENTIFICATION STUDY CHARACTERISTICS AND RISK OF BIAS TABLES APPENDIX 11: CASE IDENTIFICATION STUDY CHARACTERISTICS AND RISK OF BIAS TABLES 1 Study characteristics table... 3 2 Methodology checklist: the QUADAS-2 tool for studies of diagnostic test accuracy... 4

More information

OUTCOMES OF DICHOTOMIZING A CONTINUOUS VARIABLE IN THE PSYCHIATRIC EARLY READMISSION PREDICTION MODEL. Ng CG

OUTCOMES OF DICHOTOMIZING A CONTINUOUS VARIABLE IN THE PSYCHIATRIC EARLY READMISSION PREDICTION MODEL. Ng CG ORIGINAL PAPER OUTCOMES OF DICHOTOMIZING A CONTINUOUS VARIABLE IN THE PSYCHIATRIC EARLY READMISSION PREDICTION MODEL Ng CG Department of Psychological Medicine, Faculty of Medicine, University Malaya,

More information

Japan Journal of Medicine 2018; 1(3): doi: /jjm

Japan Journal of Medicine 2018; 1(3): doi: /jjm Jpn J Med 2018,1:3 164 Japan Journal of Medicine 2018; 1(3): 164 169. doi: 10.31488/jjm.1000112 Review article Studies on constipation of psychiatry inpatients in Tottori Medical Center Tsuruhei Sukegawa,

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Psychosis and schizophrenia in adults: treatment and management Quality standard title:

More information

Ingrezza (valbenazine)

Ingrezza (valbenazine) Ingrezza (valbenazine) Policy Number: 5.01.635 Last Review: 7/2018 Origination: 07/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Ingrezza

More information

RATING MENTAL WHOLE PERSON IMPAIRMENT UNDER THE NEW SABS: New Methods, New Challenges. CSME/CAPDA Conference, April 1, 2017

RATING MENTAL WHOLE PERSON IMPAIRMENT UNDER THE NEW SABS: New Methods, New Challenges. CSME/CAPDA Conference, April 1, 2017 RATING MENTAL WHOLE PERSON IMPAIRMENT UNDER THE NEW SABS: New Methods, New Challenges CSME/CAPDA Conference, April 1, 2017 William H. Gnam, PhD, MD, FRCPC (william.gnam@gmail.com) Consultant Psychiatrist

More information

Schizophrenia. Delusion or Reality

Schizophrenia. Delusion or Reality Schizophrenia Delusion or Reality Why Diagnose? We would even argue that the sole reason as to why clinicians should undertake a diagnostic assessment is to develop a management plan for the patient. Otherwise

More information

The Prevalence of Depression Among the Elderly in Sepang, Selangor

The Prevalence of Depression Among the Elderly in Sepang, Selangor The Prevalence of Depression Among the Elderly in Sepang, Selangor M S Sherina, MMed, L Rampal, PhD, A Mustaqim, BSc Department of Community Health, Faculty of Medicine and Health Sciences, Universiti

More information

Elements for a Public Summary. VI.2.1 Overview of disease epidemiology

Elements for a Public Summary. VI.2.1 Overview of disease epidemiology VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Schizophrenia Schizophrenia is a mental disorder often characterized by abnormal social behaviour and failure to recognize what

More information

Role of Clozapine in Treatment-Resistant Schizophrenia

Role of Clozapine in Treatment-Resistant Schizophrenia Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant

More information

NeuRA Schizophrenia diagnosis May 2017

NeuRA Schizophrenia diagnosis May 2017 Introduction Diagnostic scales are widely used within clinical practice and research settings to ensure consistency of illness ratings. These scales have been extensively validated and provide a set of

More information

Antipsychotic treatment, psychoeducation & regular follow up as a public health strategy for schizophrenia: Results from a prospective study

Antipsychotic treatment, psychoeducation & regular follow up as a public health strategy for schizophrenia: Results from a prospective study Indian J Med Res 146, July 2017, pp 34-41 DOI: 10.4103/ijmr.IJMR_838_15 Quick Response Code: Antipsychotic treatment, psychoeducation & regular follow up as a public health strategy for schizophrenia:

More information

CHAPTER IV VALIDATION AND APPLICATION OF ABERRANT BEHAVIOUR ASSESSMENT CHECKLIST PREPARED IN TELUGU LANGUAGE

CHAPTER IV VALIDATION AND APPLICATION OF ABERRANT BEHAVIOUR ASSESSMENT CHECKLIST PREPARED IN TELUGU LANGUAGE CHAPTER IV VALIDATION AND APPLICATION OF ABERRANT BEHAVIOUR ASSESSMENT CHECKLIST PREPARED IN TELUGU LANGUAGE 4.1 Translation of Aberrant Behaviour Checklist and its Validation Until now, no translation

More information

Psychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com

Psychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com Psychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com Introduction Psychotic spectrum disorders include schizotypal personality disorder, delusional disorder, brief psychotic

More information

Stigma in Patients Using Mental Health Services

Stigma in Patients Using Mental Health Services IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861Volume 17, Issue 12 Ver 2 (December 2018), PP 16-23 wwwiosrjournalsorg Stigma in Patients Using Mental Health

More information

Cocaine is a Major Risk Factor for Antipsychotic Induced Akathisia, Parkinsonism and Dyskinesia By Arija Maat, Annemarie Fouwels, Lieuwe de Haan

Cocaine is a Major Risk Factor for Antipsychotic Induced Akathisia, Parkinsonism and Dyskinesia By Arija Maat, Annemarie Fouwels, Lieuwe de Haan PB-41-3-2008-De haan.qxp 09-09-2008 15:45 Page 5 ORIGINAL RESEARCH Key Words: cannabis, cocaine, drug abuse, extrapyramidal side effects, neuroleptics, antipsychotics Cocaine is a Major Risk Factor for

More information

Quetiapine is a dibenzothiapine derivative that interacts

Quetiapine is a dibenzothiapine derivative that interacts 0271-0749/02/2204-0347/0 Journal of Clinical Psychopharmacology Vol. 22, No. 4 Copyright 2002 by Lippincott Williams & Wilkins, Inc. Printed in U.S.A. Therapeutic Tolerance and Rebound Psychosis During

More information

Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors

Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors Margaret G. Woerner, Ph.D., Jose Ma. J. Alvir, Dr.P.H., Bruce L. Saltz, M.D., Jeffrey A. Lieberman, M.D., and John M. Kane,

More information

Community Services - Eligibility

Community Services - Eligibility Community Services - Eligibility In order for DMH to reimburse care, the individual must meet both financial and clinical eligibility criteria. These criteria are described in detail in the DMH provider

More information

Schizophrenia and Other Psychotic Disorders

Schizophrenia and Other Psychotic Disorders Schizophrenia and Other Psychotic Disorders Chapter 14 This multimedia product and its contents are protected under copyright law. The following are prohibited by law: any public performance or display,

More information

Chapter 14. Psychological Disorders 8 th Edition

Chapter 14. Psychological Disorders 8 th Edition Chapter 14 Psychological Disorders 8 th Edition Abnormal Behavior Historical aspects of mental disorders F 14.1 The medical model What is abnormal behavior? 3 criteria F 14.2 Deviant Maladaptive Causing

More information

Schizoaffective Disorder

Schizoaffective Disorder Schizoaffective Disorder combination of schizophrenia symptoms (hallucinations or delusions) and mood disorder symptoms (such as mania or depression.) Controversial Requires presence of delusions for 2

More information

BGS Falls Severe mental illness, poor bone health and falls: The potential role for physical activity

BGS Falls Severe mental illness, poor bone health and falls: The potential role for physical activity Severe mental illness, poor bone health and falls: The potential role for physical activity Brendon Stubbs MCSP, PhD Head of Physiotherapy South London and Maudsley NHS Foundation Trust Post Doctoral Research

More information

Diagnostic and prognostic significance of Schneiderian first-rank symptoms: a 20-year longitudinal study of schizophrenia and bipolar disorder

Diagnostic and prognostic significance of Schneiderian first-rank symptoms: a 20-year longitudinal study of schizophrenia and bipolar disorder Available online at www.sciencedirect.com Comprehensive Psychiatry 52 (2011) 126 131 www.elsevier.com/locate/comppsych Diagnostic and prognostic significance of Schneiderian first-rank symptoms: a 20-year

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Lam RW, Levitt AJ, Levitan RD, et al. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized

More information

Schizophrenia. Psychotic Disorders. Schizophrenia. Chapter 13

Schizophrenia. Psychotic Disorders. Schizophrenia. Chapter 13 Schizophrenia Chapter 13 Psychotic Disorders Symptoms Alternations in perceptions, thoughts, or consciousness (delusions and hallucination) DSM-IV categories Schizophrenia Schizophreniform disorder Schizoaffective

More information